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1. Review the history and evidence behind risk prediction scores 
2. Assess the current evidence base for the use of imaging to guide primary 
prevention 












Coronary heart disease is the commonest cause of death across the world. The World 
Health Organisation estimates it accounts for nearly a third of all global deaths each 
year and since 1990, more people have died from cardiovascular disease than any 
other cause.1 So how can we prevent this inexorable tide of cardiovascular morbidity 
and mortality? 
 
The concept of primary prevention is rooted in history with the old adage “prevention 
is better than cure” being attributed to Deciderius Erasmus, the 15th century Dutch 
philosopher. Prevention of cardiovascular diseases, such as myocardial infarction and 
stroke, is a major goal of the medical community and is embodied in current 
international guidelines. Indeed, the use of cardiovascular risk scores to identify 
individuals at risk is the current standard of care across the world.2-6 The rationale for 
this practice is to select those individuals at greatest risk to maximise the cost-
effectiveness of treatment, without recommending therapy in the entire population. 
This is especially important given that the majority of cardiovascular events are 
unheralded, and the prognosis in those suffering myocardial infarctions without 
preceding symptoms of angina is worse.7 However, there is considerable debate 
surrounding whether this is something that risk scores can accurately do. In an area 
of practice that requires significant improvement, this article aims to look at whether 
cardiovascular imaging can be used to optimise the process of primary prevention. 
 
The Birth of Risk Scores 
 
Although many different risk scores are used throughout the world, the Framingham 
score is perhaps the most famous. Inspired by the death of President Roosevelt in 
1945 and on the back of a pandemic of the then “untreatable” cardiovascular disease, 
the United States of America established the National Heart, Lung and Blood Institute 
whose primary aim was to conduct an epidemiological study of heart disease.8 The 
Framingham Heart Study was credited with identifying the importance of blood 
pressure control in the battle to prevent heart disease. It also popularised the term ‘risk 
factor’, the articulation of which led to the development of cardiovascular risk scores.9 
Armed with the knowledge of risk factors such as systolic hypertension and 
hyperlipidaemia, studies in a primary prevention setting were conducted and 
confirmed the therapeutic and prognostic efficacy of treatment.10 For example, in the 
case of lipid control in asymptomatic hypercholesterolaemic men, the West of 
Scotland Coronary Prevention Study (WOSCOPS)11 demonstrated pravastatin 
reduced the rates of coronary heart disease death or non-fatal myocardial infarction. 
As a result of these effective therapies, interventions were focused on identifying those 
at risk of adverse cardiovascular events in an attempt to prevent them from occurring 
in the first place. Although individual risk factors are widely recognised and accepted, 
the nuance of how much risk is required before a treatment should be initiated has 
since remained a controversial topic. Over the years, many epidemiological studies 
have led to the creation of risk scores calibrated to local populations. These scores 
attempt to quantify the probability of an individual having a cardiovascular event, 
based on estimations from population studies. In 2010, the NICE guidelines suggested 
that a >30% risk of cardiovascular disease at 10-years warranted treatment with 
statins, but then subsequently reduced this to >20% and in the most recent iteration it 
is >10%.2 These cut offs are therefore somewhat arbitrary and are often based on 
issues of cost-effectiveness, societal acceptability and population prevalence of 
disease.  
 
Why Are Risk Scores Not Enough? 
 
Risk scores inevitably end up treating nearly all patients who are middle aged, given 
that age is such a dominant predictor of cardiovascular risk. Indeed, some have 
suggested all individuals over the age of 50 should receive a statin.12,13 Despite 
widespread and near universal adoption of risk scoring and the substantial associated 
healthcare resource utilisation and cost, its use is actually empirical. Several studies 
have questioned the ability of risk scores to predict events highlighting the lack of 
generalisability in broader populations and that the vast majority of younger patients 
who present with an event would not have qualified for primary prevention using risk 
scores.14,15 A recent Cochrane Systematic Review assessed the practice of using risk 
scores to select individuals for the primary prevention of cardiovascular disease.16 
Although the review identified 41 trials incorporating nearly 200,000 participants, these 
studies had a high risk of bias and were of low quality. The principal finding of the 
systematic review was that there was little or no effect on cardiovascular event rates 
when clinicians did or did not use cardiovascular risk scores (5.4% versus 5.3%; 
relative risk 1.01, 95% confidence intervals 0.95 to 1.08).  
 
There is a growing body of evidence that suggests not only a disconnect between 
primary care physicians and their willingness to prescribe statins for primary 
prevention, but also a reluctance of patients to adhere to therapy. There is major 
under-prescription in current practice with one large cohort study showing that less 
than half of over 300,000 individuals deemed “eligible” for prevention were prescribed 
a statin.17 When asked, primary care physicians cite difficulty interpreting risk 
assessment tools and their ever changing thresholds for treatment, as barriers to the 
use of statin in the primary prevention of cardiovascular disease. Primary care 
physicians also expressed fears of excessive healthcare resource utilisation and over 
medicalisation of healthy individuals.18 On a patient level, there is considerable 
difficulty in understanding the concept of risk and probabilities which alongside fear of 
side effects and conflicting reports in the media often results in resistance to taking 
statin therapy.19-21  
 
The current approach to primary prevention needs to improve and would benefit from: 
 
1. An enhanced ability to predict risk more accurately.  
2. Better compliance with lifestyle intervention and medications.  
3. Improved net clinical and cost effectiveness both for the patient and for society.  
 
Non-invasive Imaging and Primary Prevention 
 
An alternative strategy to applying scores that calculate the probabilistic risk for a 
disease is to screen for the disease. The use of imaging to guide primary prevention 
is not novel (Table 1). Although various modalities have been tested to a greater or 
lesser extent, imaging of carotid intima thickness, coronary artery calcium (CAC) 





Imaging to Enhance Risk Prediction 
 
Carotid Ultrasound 
Autopsy studies from the 1960s first suggested a correlation between carotid and 
coronary atherosclerosis.22 The Kuopio Ischaemic Heart Disease Risk Factor Study 
(KIHD) followed a large cohort of Finnish men through the late 1980s scanning more 
than 1500 carotid arteries by ultrasound. They were the first to show that those with 
carotid intimal thickening had more than double the chance of going on to having a 
coronary event.23 Carotid intimal thickness measurements can be made using B-mode 
ultrasonography of the carotid artery (Figure 1). This is a relatively inexpensive and 
readily portable method of detecting early atherosclerosis and does not require the 
use of ionising radiation.24 Since the 1980s, multiple studies and meta-analyses have 
shown that intimal thickness is a strong predictor of future vascular events.24,25  
 
In addition to the detection of disease, carotid intimal thickness can be used to track 
disease progression. Multiple meta-analyses have also reported that statin therapy is 
associated with a dose-dependent reduction in carotid intimal thickness.26,27 A review 
by the European Society of Cardiovascular Prevention and Rehabilitation (ESCPR) 
felt that there was sufficient evidence for the use of changes in carotid intimal thickness 
to be used as a measure of atherosclerotic disease.28 Along with Espeland and 
colleagues,29 they felt that progression of carotid intimal thickness met criteria of a 
surrogate for cardiovascular disease endpoints in trials assessing statin therapy.  
 
Cardiac Computed Tomography 
Coronary artery calcification is considered pathognomonic of coronary artery disease 
and can be detected and quantified on computed tomography (CT) of the chest. Such 
scans require minimal breath holding, do not require administration of intravenous 
contrast and incur less radiation than mammography or low-dose lung scanning.30 As 
a surrogate for coronary artery disease, CT calcium scoring performs better than 
carotid ultrasound at risk stratification (Figure 2).31,32  
 
The progression of coronary artery calcification is, however, a more complex topic. 
Unlike plaque thickness in B mode ultrasonography, progressive calcification is 
thought to have a stabilising effect on high-risk plaque. Indeed, studies on the effect 
of statins on coronary calcium have demonstrated continued progression of 
calcification which adds to this theory.33,34 We suspect that the ability of coronary artery 
calcium scoring to predict risk is due to the associated presence of high risk (mixed or 
non-calcific) plaque rather than representing a direct effect of the calfic plaque.35  
Indeed when assessed separately, a study of over 3000 participants found that 
progression of coronary calcium score had little to no effect on future risk prediction.36 
There is no doubt however in the power of a zero calcium score in asymptomatic 
individuals which has repeatedly demonstrated positive prognostic outcomes.37 
Ultimately, calcium scoring may therefore be seen as a measure of stable calcific 
plaques and its absence a marker of the lowest risk. How then do we detect high-risk 
plaque? Here there is growing interest in the use of computed tomography coronary 
angiography which has been validated in large randomised trials looking at patients 
with stable coronary disease (Figure 3 & 4).38,39 
 
Computed Tomography Coronary Angiography 
Although coronary artery calcification is a very good surrogate of coronary heart 
disease, it does not provide direct information about the total plaque burden or 
stenosis severity and can be absent in middle-aged patients with non-calcified plaque. 
Coronary artery calcium scoring is therefore a surrogate of disease rather than truly 
identifying the presence or absence of coronary heart disease. In this regard, 
computed tomography coronary angiography can be considered the gold standard 
non-invasive imaging technique that can detect the presence of both calcified and non-
calcified coronary heart disease with a high degree of accuracy. There are several 
avenues of novel research that are being investigated in this field. For example, a 
recent study demonstrated how quantification of the low attenuation (non-calcified) 
plaque burden, was the most powerful predictor of myocardial infarction, 
outperforming CT coronary calcium scoring, the severeity of luminal stenosis and 
cardiovascular risk factor assessment (Figure 5).40  
 
To date, computed tomography coronary angiography has not been used 
systematically to screen for disease in high risk individuals although there are ongoing 
prospective longitudinal observational studies, such as the Copenhagen General 
Population Study and the Swedish CArdioPulmonary bioImage Study (SCAPIS), 
which will inform upon the power of computed tomography coronary angiography to 
predict future risk of cardiovascular events. 
 
Imaging and Behavioural Change  
 
Carotid Ultrasound 
Compliance is a particularly difficult issue when it comes to primary prevention. 
Therapies are indicated in asymptomatic people who, in general, live active and 
fulfilled lives. Why should they take medication based on the potential of developing 
disease? Moreover, individuals may experience side-effects from treatments that 
make them feel worse, not better. Imaging has the potential to clarify the concept of 
risk and provide direct evidence of subclinical disease. Rather than providing a 
probability of developing disease, patients can visualise coronary or carotid plaque in 
their own body. This is a significant change in emphasis that can impact on behaviour. 
For example, in the visualisation of asymptomatic atherosclerotic disease for optimum 
cardiovascular prevention (VIPVIZA) trial, showing patients pictures of their diseased 
carotid arteries led to an improvement in their cardiovascular risk scores over 12 
months.41 This lends weight to the argument that patients are more likely to make 
necessary changes to their behaviour when presented with clear evidence of a 
disease process occurring in their body, rather than with the probability of a diagnosis. 
The converse is equally true. The cessation of therapies in patients who do not have 
the disease has the potential to improve their quality of life.42 
 
Cardiac Computed Tomography 
In retrospective cross-sectional studies of asymptomatic patients undergoing calcium 
scoring, more severe coronary artery calcification is associated with greater lifestyle 
modifications including medication adherence, dietary modification, weight loss, 
reduced alcohol intake and increased exercise.43-46 In a meta-analysis, a non-zero 
coronary artery calcium score was associated with an increased likelihood of 
medication initiation and continuation, dietary change (odds ratio 1.8, 95% confidence 
interval 1.4 to 2.4) and increased exercise (odds ratio 1.9 95% confidence interval 1.5 
to 2.5).47 The early identification of subclinical atherosclerosis by non-invasive imaging 
research (EISNER) trial randomised 2137 participants to risk factor management with 
and without screening with a calcium score.48 The knowledge of the calcium score 
was associated with better risk factor management with lower blood pressures, 
cholesterol concentrations, and abdominal girth.49 Indeed, the higher the calcium 
score, the greater the improvements that were seen, underlining the impact of imaging 
on physician and patient behaviour. Another small randomised trial demonstrated how 
showing patients their coronary artery calcification was associated with favourable 
changes in lifestyle such as increased medication compliance, improved lipid profile 
and reduced smoking.50  
 
Computed Tomography Coronary Angiography 
There are currently no studies that have assessed the impact of computed tomography 
coronary angiography on behaviour modification. However, studies are ongoing to 
address this issue (NCT04156061) with the aim of determining the effects on lifestyle, 
medication compliance and risk factor modification of computed tomography coronary 
angiography compared with standard risk score assessments. This study will also 
investigate whether showing individuals the images of their coronaries has a greater 
impact on their compliance and behaviour than provision of a verbal report. 
 
Imaging and Clinical Outcomes  
 
Carotid Ultrasound 
The true impact of imaging on hard clinical outcomes and cost-effectiveness requires 
randomised controlled trials. However, in the absence of such data, observational 
studies can provide some limited information. Van den Oord and colleagues 
conducted a meta-analysis of more than 32,000 patients demonstrating that the c-
statistic on an area under the curve analysis for traditional risk factors was 0.726, and 
that the addition of carotid intima-media thickness did not provide a meaningful 
increase in this risk prediction (0.729, p=0.8).51 This was further highlighted in a 
comparative study conducted by Kavousi and colleagues who calculated the net 
reclassification index (a measure of how well a new model reclassifies patients) using 
a variety of “new markers” for coronary risk prediction including carotid intimal 
thickness.52 They found only a marginal improvement when using carotid ultrasound 
(reclassifies only 1.6% of the population). The reasons for carotid imaging’s relatively 
poor performance may lie in the lack of a uniform methodology. In addition, carotid 
atherosclerosis is remote from the major cause of cardiovascular events, coronary 
artery disease. Correlation of carotid intimal thickening with the presence of coronary 
artery disease is modest and unreliable.53 This may be improved by the more 
comprehensive assessments of carotid plaque burden which can have comparable 
results to coronary calcium scoring.24,54  
 
Cardiac Computed Tomography 
To date, there have been three prospective trials that have attempted to evaluate the 
clinical and cost outcomes of coronary artery calcium scoring in an asymptomatic 
population (Table 2). The Prospective Army Coronary Calcium (PACC) study 
(n=1640) aimed to assess the impact of calcium scoring on the management of 
cardiovascular risk factors.55  Although it demonstrated the ability of calcium scanning 
to shift clinicians’ management of patients, this did not translate into a reduction in risk 
or cardiovascular events. Within this very low risk and young population (mean age 
42 years), 85% of participants had a calcium score of zero in the scanning arm which 
undoubtedly limited its ability to assess improvements in cardiovascular outcomes.49 
This again emphasises the importance of targeting risk scores or imaging to 
populations with a significant prevalence of the disease. From a health economics 
perspective, the EISNER trial showed that the use of calcium scoring did not add to 
downstream medical testing or reduce costs.48 
 
The St Francis Heart (n=1005) study was a double blinded randomised controlled trial 
where participants with a mean calcium score of ≥500 were given a combination of 
atorvastatin 20 mg, vitamin C and E, or matched placebo.56 The primary outcome was 
to assess whether aggressive control of lipid risk factors could slow the progression of 
coronary calcification and thereby reduce cardiovascular events. The investigators 
found that coronary calcification continued to progress although the rates of 
cardiovascular event did appear to improve after 5 years (p=0.08).49 This study was 
perhaps underpowered but also again raises the question about the use of coronary 
calcium scores to assess disease progression and response to therapy. Given the low 
number of events in a primary prevention population, large scale long term randomised 
trials are needed, such as the ongoing Risk Or Benefit IN Screening for Cardiovascular 
diseases (ROBINSCA) trial.57  
 
Computed Tomography Coronary Angiography 
The FACTOR-64 trial has been the only computed tomography coronary angiography 
trial in primary prevention, and it specifically recruited 900 patients with type 1 or 2 
diabetes mellitus only.58 Participants found to have coronary heart disease on 
computed tomography coronary angiography were targeted for more intensive risk 
factor modification, although 75% of trial participants were already on a statin at 
baseline. Compared to standard of care, those assigned to computed tomography 
coronary angiography had an LDL-cholesterol concentration that was 0.06 mmol/L 
lower (p=0.02) but there was no difference in blood pressure or haemoglobin A1c 
concentrations. In the intention-to-treat analysis, the primary end-point occurred in 
6.2% of the computed tomography coronary angiography group compared to 7.6% in 
the control group (hazard ratio, 0.80 [95% confidence interval, 0.49-1.32]; p=0.38). In 
the as-treated analysis, the respective event rates were 5.6% vs 7.9% (hazard ratio, 
0.69 [95% confidence interval, 0.41-1.16]; p=0.16). The failure to demonstrate a 
benefit is therefore likely to represent the inability to deliver a major difference in 
treatment and management consequent on the application of the imaging test, and a 
lack of power due to the small sample size and lower than anticipated event rate.  
 
Although not performed on an asymptomatic population, the Scottish COmputed 
Tomography of the HEART (SCOT-HEART) trial raised several interesting 
observations.42,59 First, the reduction in coronary events was independent of 
symptoms. Indeed, the point estimates suggested that patients with non-anginal chest 
pain showed at least as much benefit from computed tomography coronary 
angiography (hazard ratio 0.45, 95% confidence intervals 0.19 to 1.03) as those with 
possible angina (hazard ratio 0.60, 95% confidence intervals 0.37 to 0.96) and those 
with known coronary heart disease (hazard ratio 0.65, 95% confidence intervals 0.32 
to 1.32). Second, a large proportion (40-50%) of patients were on antiplatelet or statin 
therapy at baseline42 and, after 5 years of follow up, the overall rates of prescription of 
these drugs varied by ~10%.59 Indeed, the relative reduction in coronary events was 
similar whether participants were taking statin therapy at baseline (hazard ratio 0.57, 
95% confidence intervals 0.34 to 0.95) or not (hazard ratio 0.57, 95% confidence 
intervals 0.28 to 1.15). However, computed tomography coronary angiography guided 
management markedly increased statin use in those with non-anginal chest who had 
coronary artery disease on the computed tomography scan irrespective of the risk 
score (Figure 6).60 The overall rates of change in statin therapy therefore 
encompasses both cessation and initiation of therapy, suggesting that computed 
tomography coronary angiography is a better guide for patient management. Third, 
the risk score was a poor predictor of coronary artery disease. The average score (10-
year cardiovascular risk) was 13 (range 1-59) in patients with normal coronary arteries, 
and 23 (range 2-62) in those with obstructive coronary artery disease. Indeed, in those 
undergoing computed tomography coronary angiography, 39% of patients were 
misclassified using a score of 20, and 33% were misclassified using a score of 10. 
Finally, the prevention of myocardial infarction requires the targeting of non-
obstructive coronary artery disease as 50-65% of patients who suffered a subsequent 
myocardial infarction had non-obstructive disease on computed tomography coronary 
angiography at baseline.39,59 Thus, the relative and absolute reductions in coronary 
events were the same irrespective of symptoms, independent of baseline statin use 
or cardiovascular risk score, and driven by both non-obstructive and obstructive 
coronary artery disease.  
 
These observations form the basis for the computed tomography coronary 
angiography for the prevention of myocardial infarction (SCOT-HEART 2) trial which 
aims to recruit 6000 asymptomatic individuals and will randomise them to a 
management strategy guided by either computed tomography coronary angiography 
or a cardiovascular risk score (NCT03920176) (Table 3). This will provide the 




Prevention of cardiovascular disease is currently guided by probabilistic risk scores 
that both over and under treat individuals, commit most middle-aged people to 
pharmacotherapy, and have little evidence base. Fundamentally, imaging in 
asymptomatic people can prevent over-medicalisation of the truly healthy and promote 
treatment and risk factor modification in those with subclinical disease. The evidence 
for improved acceptance of preventative therapies and lifestyle interventions is 
growing, but we still require evidence of improved clinical outcomes. Although it is right 
that we should put these investigations through rigorous trials, we have had the 
capacity to screen for coronary artery disease for over 20 years. Only now are we 
beginning to explore what technology and innovation can do to give preventive 





In asymptomatic people: 
• Primary prevention of cardiovascular disease is currently guided by probabilistic 
risk scores that have never been prospectively validated. 
• Imaging techniques enhance the ability to predict risk over and above risk scores. 
• Imaging techniques improve compliance with medication and promote uptake of 
positive lifestyle choices. 
• Imaging has the potential to improve clinical outcomes by focusing treatments on 
patients who actually have the disease whilst simultaneously stopping treatments 



















MULTIPLE CHOICE QUESTIONS 
 
1. Which of the following is a true regarding carotid intimal thickness? (Answer: D) 
a. Carotid intimal thickness has strong evidence as a surrogate endpoint in 
cardiovascular trials assessing the efficacy of aspirin. 
b. Carotid intimal thickness has strong evidence as a surrogate endpoint in 
cardiovascular trials assessing the efficacy of any lipid lowering drug. 
c. Progression of carotid intimal thickness is a poor marker of the 
atherosclerotic disease process. 
d. Progression of carotid intimal thickness is better than progression of 
coronary artery calcium scoring as a surrogate endpoint in cardiovascular 
trials assessing the efficacy of statin therapy. 
e. Carotid intimal thickness is the best means of assessing the extent 
atherosclerosis in the coronary artery. 
 
2. Which of the following is true regarding the use of Cardiac Computed 
Tomography? (Answer: D) 
a. Coronary calcium is a marker of high-risk coronary artery plaque. 
b. It requires high dose of radiation. 
c. Statins reduce the progression of coronary calcification. 
d. It is better at predicting cardiovascular risk compared to carotid intimal 
thickness.  
e. A calcium score of zero means patients will never suffer a cardiovascular 
event. 
 
3. Which of the following is a randomised trial that assessed the use of computed 











4. Which of the following is true regarding the use of Computed Tomography 
Coronary Angiography? (Answer: C) 
a. Uses the same amount of radiation as mammography or low dose lung 
scanning 
b. Is poor at determining luminal stenosis. 
c. Can be used to identify high risk plaque. 
d. Has been shown to positively affect physician prescription and patient 
compliance with preventative medication. 
e. Has been proven to improve prognosis in a primary prevention setting. 
 
5. Which of the following is currently recommended by European guidelines for 
primary prevention? (Answer: A) 
a. All patients should have a risk score calculated. 
b. All patients should undergo ultrasound assessment of carotid intimal 
thickness as part of their risk assessment. 
c. All patients should undergo cardiac computed tomography to calculate 
coronary calcium score as routine. 
d. All patients should undergo computed tomography coronary angiography 
as part of their risk assessment. 
e. Imaging is not recommended for primary prevention purposes. 
 
6. Who was responsible for funding the Framingham Heart Study? (Answer: B) 
a. The European Society for Cardiovascular Prevention and Rehabilitation. 
b. The National Heart, Lung and Blood Institute. 
c. The American College of Cardiology. 
d. The National Institute for health and Care Excellence. 
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